8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 16, 2026·SEC
Acumen Pharmaceuticals, Inc.(ABOS)Earnings, Financials & Key Ratios
ABOS•NASDAQ
Price updated Jun 19, 2026
AboutAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Show more
- Revenue$0
- EBITDA-$124M-8.6%
- Net Income-$121M-18.6%
- EPS (Diluted)-2.00-17.0%
- ROE-96.2%-111.0%
ABOS Key Insights
Acumen Pharmaceuticals, Inc. (ABOS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 75.3% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ABOS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABOS Price & Volume
Acumen Pharmaceuticals, Inc. (ABOS) stock price & volume — 10-year historical chart
Loading chart...
ABOS Growth Metrics
Acumen Pharmaceuticals, Inc. (ABOS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.61%
Return on Capital
10 Years-50.66%
5 Years-37.63%
3 Years-50.47%
Last Year-81.41%
ABOS Recent Earnings
Acumen Pharmaceuticals, Inc. (ABOS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.33+18.1%
$0.40
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.41+18.0%
$0.50
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.44+30.2%
$0.63
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.68-25.9%
$0.54
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.33vs $0.40+18.1% | — |
| Q2 2026 | Mar 26, 2026 | $0.41vs $0.50+18.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.44vs $0.63+30.2% | — |
| Q3 2025 | Aug 12, 2025 | $0.68vs $0.54-25.9% | — |
Based on last 12 quarters of dataView full earnings history →
ABOS Peer Comparison
Acumen Pharmaceuticals, Inc. (ABOS) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ATNM | 32.32M | 1.03 | -0.95 | -260.79% | -218.67% | 0.22 | ||
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 ACIU | 244.26M | 2.40 | -2.74 | -86.92% | -19.69% | -101.6% | 0.10 | |
 ANVS | 34.43M | 1.75 | -1.25 | -318.08% | ||||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% |
Compare ABOS vs Peers
Acumen Pharmaceuticals, Inc. (ABOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABOS Income Statement
Acumen Pharmaceuticals, Inc. (ABOS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.7M | 1.44M | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -15.38% | -100% | - | - | - | - | - |
Cost of Goods Sold | 8.58M | 8M | 12.3M | 0 | 0 | 0 | 0 | 46K |
COGS % of Revenue | 505.36% | 556.89% | - | - | - | - | - | - |
Gross Profit | -6.88M▲ 0% | -6.56M▲ 4.6% | -12.3M▼ 87.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -46K▲ 0% |
Gross Margin % | -405.36% | -456.89% | - | - | - | - | - | - |
Gross Profit Growth % | - | 4.62% | -87.55% | 100% | - | - | - | - |
Operating Expenses | 926K | 1.35M | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M | 114.56M |
OpEx % of Revenue | 54.57% | 94.08% | - | - | - | - | - | - |
Selling, General & Admin | 926K | 1.35M | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M | 18.46M |
SG&A % of Revenue | 54.57% | 94.08% | - | - | - | - | - | - |
Research & Development | 8.58M | 8M | 12.3M | 32.36M | 42.32M | 93.8M | 104.89M | 96.1M |
R&D % of Revenue | 505.36% | 556.89% | - | - | - | - | - | - |
Other Operating Expenses | -8.58M | -8M | -12.3M | 0 | 0 | 0 | 0 | 0 |
Operating Income | -7.8M▲ 0% | -7.91M▼ 1.4% | -19.58M▼ 147.5% | -45.24M▼ 131.0% | -61.14M▼ 35.2% | -114.02M▼ 86.5% | -123.83M▼ 8.6% | -114.61M▲ 0% |
Operating Margin % | -459.93% | -550.97% | - | - | - | - | - | - |
Operating Income Growth % | - | -1.37% | -147.52% | -130.99% | -35.15% | -86.49% | -8.61% | - |
EBITDA | 0 | -7.91M | -19.58M | -45.07M | -60.95M | -113.84M | -123.65M | -114.43M |
EBITDA Margin % | - | -550.97% | - | - | - | - | - | - |
EBITDA Growth % | - | - | -147.47% | -130.17% | -35.25% | -86.76% | -8.62% | 9.5% |
D&A (Non-Cash Add-back) | 7.8M | 0 | 4K | 169K | 184K | 178K | 184K | 185K |
EBIT | -7.8M | -7.91M | -19.58M | -42.86M | -51.79M | -98.26M | -117.11M | -110.49M |
Net Interest Income | 45K | 1K | 84K | 2.39M | 10.21M | 10.25M | 3.22M | 1.77M |
Interest Income | 45K | 1K | 84K | 2.39M | 10.79M | 14.32M | 7.45M | 6.04M |
Interest Expense | 0 | 0 | 0 | 0 | 581K | 4.07M | 4.22M | 4.27M |
Other Income/Expense | -102K | 587K | -81.02M | 2.38M | 8.77M | 11.69M | 2.5M | 1.33M |
Pretax Income | -7.91M▲ 0% | -7.33M▲ 7.4% | -100.61M▼ 1273.5% | -42.86M▲ 57.4% | -52.37M▼ 22.2% | -102.33M▼ 95.4% | -121.33M▼ 18.6% | -113.28M▲ 0% |
Pretax Margin % | -465.94% | -510.1% | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -7.91M▲ 0% | -7.33M▲ 7.4% | -100.61M▼ 1273.5% | -42.86M▲ 57.4% | -52.37M▼ 22.2% | -102.33M▼ 95.4% | -121.33M▼ 18.6% | -113.28M▲ 0% |
Net Margin % | -465.94% | -510.1% | - | - | - | - | - | - |
Net Income Growth % | - | 7.36% | -1273.46% | 57.4% | -22.2% | -95.39% | -18.57% | 2.56% |
Net Income (Continuing) | -7.91M | -7.33M | -100.61M | -42.86M | -52.37M | -102.33M | -121.33M | -113.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.27▲ 0% | -0.26▲ 3.7% | -2.63▼ 911.5% | -1.06▲ 59.7% | -1.08▼ 1.9% | -1.71▼ 58.3% | -2.00▼ 17.0% | -1.79▲ 0% |
EPS Growth % | - | 3.7% | -911.54% | 59.7% | -1.89% | -58.33% | -16.96% | 3.61% |
EPS (Basic) | -0.20 | -0.26 | -2.63 | -1.06 | -1.08 | -1.71 | -2.00 | - |
Diluted Shares Outstanding | 28.65M | 28.65M | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M | 63.22M |
Basic Shares Outstanding | 28.65M | 28.65M | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M | 63.22M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ABOS Balance Sheet
Acumen Pharmaceuticals, Inc. (ABOS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.18M | 44.43M | 198.66M | 180.33M | 246.62M | 178.31M | 122.25M | 133.09M |
Cash & Short-Term Investments | 6.55M | 43.78M | 194.24M | 177.6M | 243.52M | 171.56M | 116.86M | 128.4M |
Cash Only | 6.55M | 43.78M | 122.16M | 130.1M | 66.89M | 35.63M | 53.99M | 51.8M |
Short-Term Investments | 0 | 0 | 72.08M | 47.5M | 176.64M | 135.93M | 62.88M | 76.6M |
Accounts Receivable | 30K | 109K | 0 | 0 | 225K | 0 | 625K | 0 |
Days Sales Outstanding | 6.45 | 27.71 | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 199K | 0 | 159K | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 7K | 447K | 2.83M | 1.42M | 1.96M | 5.73M | 4.76M | 4.7M |
Total Non-Current Assets | 144K | 0 | 31.67M | 16.26M | 63.51M | 60.69M | 581K | 535K |
Property, Plant & Equipment | 0 | 0 | 36K | 270K | 503K | 339K | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 169K | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 31.62M | 15.84M | 62.55M | 59.97M | 0 | 32.47M |
Other Non-Current Assets | 144K | 0 | 14K | 151K | 285K | 379K | 581K | 535K |
Total Assets | 7.32M▲ 0% | 44.43M▲ 506.8% | 230.33M▲ 418.4% | 196.59M▼ 14.6% | 310.13M▲ 57.8% | 238.99M▼ 22.9% | 122.83M▼ 48.6% | 133.63M▲ 0% |
Asset Turnover | 0.23x | 0.03x | - | - | - | - | - | 0.00x |
Asset Growth % | - | 506.79% | 418.42% | -14.65% | 57.75% | -22.94% | -48.6% | -170.48% |
Total Current Liabilities | 1.34M | 6.37M | 5.15M | 7.81M | 12.97M | 27.61M | 30.01M | 29.23M |
Accounts Payable | 223K | 531K | 1.09M | 1.64M | 1.38M | 5.65M | 554K | 1.66M |
Days Payables Outstanding | 9.49 | 24.24 | 32.27 | - | - | - | - | 9.91K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 8.91M | 14.12M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 614K | 5.5M | 2.96M | 131K | 3.9M | 230K | 20.54M | 13.45M |
Current Ratio | 5.35x | 6.98x | 38.60x | 23.08x | 19.01x | 6.46x | 4.07x | 4.55x |
Quick Ratio | 5.35x | 6.98x | 38.60x | 23.06x | 19.01x | 6.45x | 4.07x | 4.55x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 17.4M | 56.65M | 0 | 0 | 30.18M | 29.57M | 22.4M | 16.92M |
Long-Term Debt | 0 | 0 | 0 | 0 | 27.34M | 29.42M | 22.4M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 284K | 150K | 0 | 116K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17.4M | 56.65M | 0 | 0 | 2.56M | 0 | 0 | 16.92M |
Total Liabilities | 18.74M | 63.02M | 5.15M | 7.81M | 43.15M | 57.18M | 52.4M | 46.15M |
Total Debt | 0 | 0 | 0 | 105K | 28.49M | 29.7M | 31.31M | 14.12M |
Net Debt | -6.55M | -43.78M | -122.16M | -130M | -38.4M | -5.92M | -22.68M | -37.67M |
Debt / Equity | - | - | - | 0.00x | 0.11x | 0.16x | 0.44x | 0.16x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.12x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.33x |
Interest Coverage | - | - | - | - | -89.14x | -24.15x | -27.73x | -25.88x |
Total Equity | -11.42M▲ 0% | -18.59M▼ 62.8% | 225.18M▲ 1311.2% | 188.78M▼ 16.2% | 266.97M▲ 41.4% | 181.82M▼ 31.9% | 70.43M▼ 61.3% | 87.48M▲ 0% |
Equity Growth % | - | -62.79% | 1311.25% | -16.17% | 41.42% | -31.9% | -61.26% | -214.13% |
Book Value per Share | -0.40 | -0.65 | 5.88 | 4.65 | 5.49 | 3.03 | 1.16 | 1.38 |
Total Shareholders' Equity | -11.42M | -18.59M | 225.18M | 188.78M | 266.97M | 181.82M | 70.43M | 87.48M |
Common Stock | 0 | 0 | 4K | 4K | 6K | 6K | 6K | 7K |
Retained Earnings | -19.64M | -26.96M | -127.57M | -170.43M | -222.8M | -325.13M | -446.46M | -467.2M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -231K | -751K | 312K | -48K | 83K | 21K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABOS Cash Flow Statement
Acumen Pharmaceuticals, Inc. (ABOS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.82M | -7.45M | -17.96M | -35.15M | -43.06M | -86.22M | -115.54M | -105.55M |
Operating CF Margin % | -401.77% | -518.8% | - | - | - | - | - | - |
Operating CF Growth % | - | -9.27% | -141.09% | -95.72% | -22.5% | -100.2% | -34.01% | -57.24% |
Net Income | -7.91M | -7.33M | -100.61M | -42.86M | -52.37M | -102.33M | -121.33M | -113.28M |
Depreciation & Amortization | 0 | 0 | 4K | 169K | 184K | 178K | -751K | 833K |
Stock-Based Compensation | 174K | 154K | 922K | 3.06M | 6.14M | 9.63M | 9.85M | 4.92M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 147K | -586K | 81.42M | 487K | -888K | -5.35M | 1.81M | 5.48M |
Working Capital Changes | 768K | 307K | 298K | 3.99M | 3.87M | 11.65M | -5.12M | -3.5M |
Change in Receivables | 200K | -79K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 110K | 308K | 557K | 552K | -261K | 4.27M | -5.09M | 545K |
Cash from Investing | 0 | 0 | -104.12M | 39.19M | -171.67M | 48.03M | 133.93M | 91.44M |
Capital Expenditures | 0 | 0 | -40K | -161K | -21K | -16K | -88K | -9K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | -39.35K | 3K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 39.35K | 0 | 0 | 0 | 0 |
Cash from Financing | 6.24M | 44.67M | 200.47M | 3.91M | 151.75M | 6.93M | -34K | 35.74M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 30M | -739K | 0 | 0 |
Equity Issued (Net) | 6.23M | 44.67M | 198.59M | 3.79M | 121.9M | 7.9M | -34K | 147K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -41K | -73K | 0 |
Other Financing | 7K | 0 | 1.88M | 115K | -151K | -230K | 0 | 35.6M |
Net Change in Cash | -579K▲ 0% | 37.23M▲ 6529.2% | 78.39M▲ 110.6% | 7.94M▼ 89.9% | -62.98M▼ 893.3% | -31.26M▲ 50.4% | 18.36M▲ 158.7% | 21.64M▲ 0% |
Free Cash Flow | -6.82M▲ 0% | -7.45M▼ 9.3% | -18M▼ 141.6% | -35.31M▼ 96.2% | -43.09M▼ 22.0% | -86.23M▼ 100.1% | -115.63M▼ 34.1% | -105.55M▲ 0% |
FCF Margin % | -401.77% | -518.8% | - | - | - | - | - | - |
FCF Growth % | - | -9.27% | -141.62% | -96.18% | -22.01% | -100.14% | -34.09% | -2.92% |
FCF per Share | -0.24 | -0.26 | -0.47 | -0.87 | -0.89 | -1.44 | -1.91 | -1.67 |
FCF Conversion (FCF/Net Income) | 0.86x | 1.02x | 0.18x | 0.82x | 0.82x | 0.84x | 0.95x | 0.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 740K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABOS Key Ratios
Acumen Pharmaceuticals, Inc. (ABOS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -97.4% | -20.71% | -22.98% | -45.6% | -96.2% | -123.07% |
Return on Invested Capital (ROIC) | - | -72.26% | -41.94% | -31.91% | -42.28% | -83.06% | -120.6% |
Gross Margin | -456.89% | - | - | - | - | - | - |
Net Margin | -510.1% | - | - | - | - | - | - |
Debt / Equity | - | - | 0.00x | 0.11x | 0.16x | 0.44x | 0.16x |
Interest Coverage | - | - | - | -89.14x | -24.15x | -27.73x | -25.88x |
FCF Conversion | 1.02x | 0.18x | 0.82x | 0.82x | 0.84x | 0.95x | 0.93x |
Revenue Growth | -15.38% | -100% | - | - | - | - | - |
Related:ABOS Dividend History·ABOS Revenue History·ABOS Price History·ABOS P/E History·ABOS Financial Ratios·ABOS Institutional Holders
ABOS SEC Filings & Documents
Acumen Pharmaceuticals, Inc. (ABOS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABOS Frequently Asked Questions
Acumen Pharmaceuticals, Inc. (ABOS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Acumen Pharmaceuticals, Inc. (ABOS) grew revenue by 0.0% over the past year. Growth has been modest.
Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $113.3M for fiscal year 2025.
Dividend & Returns
Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity (ROE) of -96.2%. Negative ROE indicates the company is unprofitable.
Acumen Pharmaceuticals, Inc. (ABOS) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.